[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:t-cell-non-hodgkin-lymphoma:cd70-antigen":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"T-Cell Non-Hodgkin Lymphoma","CD70 Antigen",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[12],"Phase 1","RECRUITING","2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07297160","CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:46.951087Z","2026-05-05T02:43:27.644388Z"]